An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 14, Iss. 6, 2015-08 ,pp. : 804-810

Bentham Science Publishers

Access to resources Recommend Favorite

A Population Approach to Characterize Interferon Beta‐1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 5, 2015-05 ,pp. : 295-304

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis

By Comi Giancarlo   Hartung Hans-Peter   Kurukulasuriya Nuwan C   Greenberg Steven J   Scaramozza Matthew  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 1, 2013-01 ,pp. : 123-136

Informa Healthcare

Access to resources Recommend Favorite

Long-Term Cost Effectiveness of Interferon- -1a in the Treatment of Relapsing-Remitting Multiple Sclerosis: An Econometric Model

By Lepen C.  

Clinical Drug Investigation, Vol. 23, Iss. 9, 2003-01 ,pp. : 571-581

Adis International

Access to resources Recommend Favorite

Comparative Assessment of Immunomodulating Therapies for Relapsing-Remitting Multiple Sclerosis

By Khan O.   Zabad R.   Caon C.   Zvartau-Hind M.   Tselis A.   Lisak R.  

CNS Drugs, Vol. 16, Iss. 8, 2002-01 ,pp. : 563-578

Adis International

Access to resources Recommend Favorite